The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity.

Methods: We retrospectively reviewed the medical records of IBD patients who visited Asan Medical center. We used a large, well-characterized referral center-based cohort. The clinical features of IBD patients with body mass index (BMI) over 30 and matched controls with BMI under 30 were compared.

Results: Among the 6,803 IBD patients enrolled in the Asan IBD Registry between June 1989 and December 2016, we identified 16 patients with Crohn's disease (CD) and 27 patients with ulcerative colitis (UC) whose BMI was over 30 at the time of diagnosis. Their clinical characteristics and course were compared with those of 64 and 108 matched patients with CD and UC, respectively. There were no significant differences in the risk of using steroids (hazards ratio (HR) = 0.633 and =0.254), immunomodulators (HR = 0.831 and =0.517), and anti-tumor necrosis factor (TNF) therapy (HR = 1.539 and =0.351) and risk of bowel resections (HR = 1.858 and =0.231) between CD patients with BMI over 30 and those with BMI under 30; similarly, UC patients did not show significant differences in the risk of using steroids (HR = 0.613 and =0.145), immunomodulators (HR = 0.492 and =0.111), anti-TNF therapy (HR = 0.385 and =0.095), and risk of colectomy (HR = 0.262 and =0.104). In the subgroup analysis, under-weight UC patients had a higher cumulative probability of needing steroids (HR = 0.2510 and =0.042), needing immunomodulators (HR = 0.097 and =0.014), and a higher risk of receiving colectomy (HR = 0.024 and =0.019) than obese UC patients.

Conclusions: Obese IBD patients with CD or UC did not show significantly different clinical features from nonobese IBD patients.